US4834971032
© BusinessWire
22.12.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025.
“The US launch of EKTERLY is progressing with significant momentum, driven by strong early demand and rapid adoption among physicians and people living with HAE. We continue to see enc...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), as well as physician and patient survey and consensus study data highlighting the substantial unmet need for sa...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
05.11.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences:
Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST
Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 1:...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.11.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company’s third quarter financial results and provide an operational update.
The live audio webcast will be accessible on the Investors section of the Company’s website at www.ir.kalvista.com/event-ca...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida from November 6–10, 2025.
The lake-breaking oral pre...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), presented at the 20th German Allergy Congress in Düsseldorf, Germany from October 2–4, 2025. Across multiple ePoster presentations...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025.
“I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY,” said Ben Palleiko, Chief Executive Officer of Kal...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 30,000 shares of KalVista common stock on October 1, 2025 as inducements material to each employee entering into employment with KalVista. T...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig’s appointment to the Audit Committee, Nancy Stuart will transition off the Aud...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress taking place in Düsseldorf, Germany from October 2–4, 2025.
Details are as follows:
Thursday, October 2 at 4:00–5:15 pm CEST:
Time to End of Progression of Hereditary Angioedema Attacks T...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
KALV
LISTED
NASDAQ
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
News Preview
KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
24.09.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes
News Preview
KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, have approved EKTERLY® (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 year...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025.
“This quarter marked a defining moment in the history of KalVista with the FDA approval of EKTERLY—the first and only oral on-demand treatment for HAE,” stated Ben Palleiko, CEO of KalVist...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for the fiscal quarter ended July 31, 2025.
The webcast can be accessed on the Investors section of the Company’s website at Kalvis...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 5,000 shares of KalVista common stock on September 1, 2025 as inducements material to each employee entering into employment with KalVista....
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 a.m. ET.
A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be availabl...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for sebetralstat, a novel oral plasma kallikrein inhibitor, for symptomatic treatment of acute attacks of hereditary...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has granted marketing authorization for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.
“The FDA approval of EKTERLY represents a major milestone—not only as the first commercial product for KalVista, but more importantly, as the first and only oral on-demand therapy for people...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-de...
Themefolio
Profiler
Peergroup
© BusinessWire
02.07.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on July 1, 2025 as inducements material to each employee entering into employment with KalVista. The...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom that underscores the critical role of effective on-demand (OD) treatment for HAE attacks among patients receiving long-term prophylaxis (LTP).
Sebet...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company’s investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company o...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025.
Details are as follows:
Friday, June 13
Potential for Sebetralstat to Address Pseudo-allergic...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 50,000 shares of KalVista common stock on June 1, 2025 as inducements material to each employee entering into employment with KalVista. The...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. Thes...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 a.m. ET.
A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalV...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming congresses taking place concurrently from May 29–June 1, 2025: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The presentations w...
Themefolio
Profiler
Peergroup
© BusinessWire
02.05.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m. ET.
A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfr...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 87,000 shares of KalVista common stock on April 1, 2025 as inducements material to each employee entering into employment with KalVista. The...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET.
A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE).
“We're proud to share that we achieved target...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update.
"Sebetralstat is poised to be the first and only oral on-demand treatment for HAE, with the potential to become the foundational treatment for this disease," said Ben Palleiko, Ch...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company’s investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on March 3, 2025 as inducements material to each employee entering into employment with KalVista. The...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from Feb...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences:
TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:10 p.m. ET in Boston, MA
Leerink Partners 2025 Global Healthcare Conference on Monday, March 10, 2025, at...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025.
The following poster presentations will take p...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting taking place in Waimea, HI from February 9-13, 2025.
Raffi Tachdjian, MD, MPH, Associate Clinical Professor of Medic...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted fifty-two newly-hired employees inducement options to purchase an aggregate of 261,000 shares of KalVista common stock on February 3, 2025 as inducements material to each employee entering into employment with Kal...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
KALV
LISTED
NASDAQ
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel, investigational oral plasma kallikrein inhibitor...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with KalVista. T...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
KALV
LISTED
NASDAQ
KalVista Appoints Jeb Ledell as Chief Operating Officer
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry.
“I am pleased to welcome Jeb to KalVista at this key...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for heredit...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December 2, 2024 as inducements material to each employee entering into employment with KalVista....
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success.
“I am pleased to welcome Dr. Reid, with his deep expertise i...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences:
Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST
Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT
Each p...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVist...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the “Offering”). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, co...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised of a $100 million upfront payment, a one-time $22 million optional payment upon U.S. product approval, and up to $57 million in a sales-based mileston...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024.
Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster presentation at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Boston, MA from October 24-28. Presentations include:
Patient-Reported Anxiety Impacts Utilizati...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark, October 4 - 5, 2024. These data were generated in the KONFID...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 31,000 shares of KalVista common stock on October 1, 2024 as inducements material to each employee entering into employment with KalVista. T...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
KALV
LISTED
NASDAQ
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced Marketing Authorization Application (MAA) submissions to the regulatory authorities in the United Kingdom, Switzerland, Australia, and Singapore for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
